Not recruiting
Migraine
Not recruitingInvestigational
Study on Atogepant for Preventing Menstrual Migraine in Women
Investigational
Countries:
Germany
Germany- Participants:18–64 years
- Substances:Atogepant
Find therapies in clinical trials near you – page 9
- recruiting
- 3 962
- countries
- 28
- conditions
- 2 101
3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today
147 trials match your criteria
Not recruiting
Epilepsy
Not recruitingRegistered drug
Study on the Effectiveness and Safety of Levetiracetam XR for Patients with Drug-Resistant Partial Onset Epilepsy
Registered drug
- Disease:Epilepsy
- Substances:Levetiracetam
Countries:Germany
Germany- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Levetiracetam
Not recruiting
Generalised tonic-clonic seizure+1
Not recruitingInvestigationalNo placebo
Study on PRAX-628 for Adults with Focal Onset or Generalized Tonic-Clonic Seizures
InvestigationalNo placebo
- Disease:Generalised tonic-clonic seizurePartial seizures
- Substances:Prax-628
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Prax-628
Not recruiting
Multiple sclerosis
Not recruitingInvestigational
Study on Frexalimab for Adults with Nonrelapsing Secondary Progressive Multiple Sclerosis
Investigational
- Disease:Multiple sclerosis
- Substances:Frexalimab
Countries:Germany
Germany- Participants:18–64 years
- Substances:Frexalimab
Not recruiting
Multiple sclerosis relapse
Not recruitingRegistered drugNo placebo
Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis
Registered drugNo placebo
- Disease:Multiple sclerosis relapse
- Substances:OfatumumabA/Darwin/6/2021(H3N2)-Like Strain (A/Darwin/11/2021, Wild Type)+42
Countries:Germany
Germany- Participants:18–64 years
- Substances:Ofatumumab
Not recruiting
Plasma cell myeloma
Not recruitingRegistered drugNo placebo
Study on Adding Isatuximab to Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma
Registered drugNo placebo
- Disease:Plasma cell myeloma
- Substances:BortezomibDexamethasone+2
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Bortezomib
Not recruiting
CDKL5 deficiency disorder
Not recruitingRegistered drug
Study on the Effectiveness and Safety of Fenfluramine Hydrochloride for Patients with CDKL5 Deficiency Disorder
Registered drug
- Disease:CDKL5 deficiency disorder
- Substances:Fenfluramine Hydrochloride
Countries:Germany
Germany- Participants:0–17 years · 18–64 years
- Substances:Fenfluramine Hydrochloride
Not recruiting
Gastrooesophageal cancer
Not recruitingRegistered drugNo placebo
Study on Atezolizumab with Drug Combination for Patients with Gastric Cancer and Esophagogastric Junction Adenocarcinoma
Registered drugNo placebo
- Disease:Gastrooesophageal cancer
- Substances:AtezolizumabDocetaxel+3
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Atezolizumab
Not recruiting
Breast cancer+7
Not recruitingRegistered drugNo placebo
Study of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment
Registered drugNo placebo
- Disease:Breast cancerTriple negative breast cancer+6
- Substances:CapecitabineCarboplatin+2
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Capecitabine
Not recruiting
Partial seizures
Not recruitingInvestigational
Study on the Safety and Effectiveness of Azetukalner for Adults with Focal Epilepsy Taking 1 to 3 Anti-Seizure Medications
Investigational
- Disease:Partial seizures
- Substances:Azetukalner
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Azetukalner
Not recruiting
Partial seizures
Not recruitingInvestigational
Study on the Effectiveness and Safety of BHV-7000 for Adults with Refractory Focal Onset Epilepsy
Investigational
- Disease:Partial seizures
- Substances:Bhv-7000
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Bhv-7000
Not recruiting
Plasma cell myeloma
Not recruitingRegistered drugNo placebo
Study on Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed High-Risk Multiple Myeloma Patients
Registered drugNo placebo
- Disease:Plasma cell myeloma
- Substances:CarfilzomibIsatuximab+1
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Carfilzomib